Moderna shares down after pulling Covid-flu combo vaccine application
Moderna has “voluntarily” withdrawn its application to the US Food and Drug Administration (FDA) for approval of its Covid-19 and …
Post
-
-
Can pharma tariffs “Make America Manufacture Again”?
As President Trump continues to signal import tariffs on pharmaceuticals to bolster US manufacturing, experts warn this could hike costs …
-
Viz.ai, Sanofi and Regeneron to link for COPD management
Viz.ai is to enter a multi-year collaboration with Sanofi and Regeneron aimed at deploying and assessing an AI-powered workflow solution …
-
Navigating new EU regulations in the clinical supply chain
The latest EU clinical trial regulations must be carefully understood. The Clinical Trial Regulation (CTR) was introduced in the EU …
-
ATS 2025: Real-world cohort study aligns with GSK depemokimab narrative
On 20 May at the American Thoracic Society (ATS) 2025 conference in San Francisco, investigators from the Analysis Group, a …
-
WHO secures 20% funding increase amid US shortfall
Member countries of the World Health Organization (WHO) will pay 20% more in membership fees as part of a revamped …
-
ATS 2025: GSK strengthens argument for twice-annual depemokimab
On 20 May 2025 at the American Thoracic Society (ATS) International Conference in San Francisco, a poster presentation by GlaxoSmithKline …
-
BioNTech to invest up to $1.34bn in UK R&D
BioNTech has made a grant agreement with the UK government to expand its research and development (R&D) activities for medicines, …
-
FDA to restrict Covid-19 booster doses to older adults
The US Food and Drug Administration (FDA) is set to restrict Covid-19 booster doses to older adults and those at …
-
HHS sets “most favoured nation” pricing targets for drug makers
The US Department of Health and Human Services (HHS) said it is “taking immediate steps” to implement a recent Executive …
-
China’s mAb and ADC licensing was 3xUS’s in 2024 — will trade tensions slow it?
China’s biopharmaceutical sector saw a rise in oncology drug licensing deals in 2024, particularly for monoclonal antibodies (mAbs) and antibody-drug …
-
ATS 2025: Sanofi and Regeneron to launch new AIM4 trial for personalised asthma care
At the American Thoracic Society (ATS) 2025 Congress on 19 May, Sanofi and Regeneron announced the launch of a new …
-
ATS 2025: ETI-linked mucus clearance tied to lung function gains in paediatric CF
On 19 May, at the 2025 American Thoracic Society (ATS) International Conference, researchers from Cincinnati Children’s Hospital presented compelling evidence …
-
Skye and Arecor to develop higher formulation of CB1 inhibitor
Skye Bioscience has partnered with Arecor Therapeutics to develop a higher formulation of the former’s obesity candidate nimacimab, a cannabinoid receptor …
-
London Biotechnology Show Makes Grand Return to Unveil Cutting-edge Advances in Health & Medicine
The inaugural London Biotechnology Show was a major hit with over 3,000 attendees present at the event, including representatives from …
